What is Immune Design Corp.'s stock symbol?
Immune Design Corp. trades on the NASDAQ under the ticker symbol "IMDZ."
Where is Immune Design Corp.'s stock going? Where will Immune Design Corp.'s stock price be in 2017?
4 analysts have issued 12 month price objectives for Immune Design Corp.'s stock. Their forecasts range from $15.00 to $15.00. On average, they anticipate Immune Design Corp.'s stock price to reach $15.00 in the next twelve months.
When will Immune Design Corp. announce their earnings?
Immune Design Corp. is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
What are analysts saying about Immune Design Corp. stock?
Here are some recent quotes from research analysts about Immune Design Corp. stock:
According to Zacks Investment Research, "Immune Design’s primary candidates, CMB305 and G100, are being evaluated for solid tumor, and merkel cell carcinoma (MCC) and sarcoma, respectively. We are positive on its strategic agreements with companies like Sanofi, Roche, Merck and AstraZeneca, which not only validate its GLAAS platform, but also provide the company with funds in the form of collaboration and license revenues. However, the company is highly dependent on its collaboration partners for top-line growth. Although such collaborations boost the company’s pipeline development, dependence on other companies for revenue growth increases its vulnerability. Moreover, the company’s shares have underperformed the Medical-Drugs industry in the past one year. Loss estimates are stable ahead the company's Q4 release." (1/17/2017)
Wells Fargo & Company analysts commented, "We view CB1158 as option value for CALA shares and are impressed with pre-clinical data suggesting activity in checkpoint inhibitor failure." (5/11/2016)
Who owns Immune Design Corp. stock?
Immune Design Corp.'s stock is owned by a number of of institutional and retail investors. Top institutional investors include ProQuest Associates IV LLC (7.72%), Franklin Resources Inc. (2.91%), FMR LLC (1.75%), State Street Corp (0.93%), Alyeska Investment Group L.P. (0.66%) and Oxford Asset Management (0.40%). Company insiders that own Immune Design Corp. stock include Carlos V Paya, Franklin M Berger, Group L P Column, Lewis W Coleman, Proquest Investments Iv, LP, Stephen R Brady and Wayne Gombotz.
Who sold Immune Design Corp. stock? Who is selling Immune Design Corp. stock?
Immune Design Corp.'s stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Franklin Resources Inc. and FMR LLC. Company insiders that have sold Immune Design Corp. stock in the last year include Carlos V Paya, Franklin M Berger, Lewis W Coleman and Stephen R Brady.
Who bought Immune Design Corp. stock? Who is buying Immune Design Corp. stock?
Immune Design Corp.'s stock was acquired by a variety of institutional investors in the last quarter, including Oxford Asset Management, Perceptive Advisors LLC, State Street Corp and Alyeska Investment Group L.P.. Company insiders that have bought Immune Design Corp. stock in the last two years include Franklin M Berger, Group L P Column, Lewis W Coleman and Stephen R Brady.
How do I buy Immune Design Corp. stock?
Shares of Immune Design Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Immune Design Corp. stock cost?
One share of Immune Design Corp. stock can currently be purchased for approximately $5.50.